University of California Riverside School of Medicine
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Maguire, Gerald
NCT05628103: A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Completed
3
101
US
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
04/24
04/24
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting
3
150
Europe, Canada, US, RoW
Ecopipam, Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Syndrome
11/24
03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Active, not recruiting
3
196
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
12/24
12/24
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Terminated
3
83
Europe, Canada, Japan, US
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.
Depressive Episodes, Bipolar I Depression
10/23
10/23
NCT01908192 / 2017-001168-39: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Terminated
2/3
60
US, RoW
NaBen®, Placebo
SyneuRx International (Taiwan) Corp
Schizophrenia
10/23
10/23
NCT05583955: A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

Completed
2
75
US, RoW
NOE-105, Escalating dose levels of NOE-105, Placebo, Placebo to match
Noema Pharma AG
Childhood-Onset Fluency Disorder
10/23
11/23

Download Options